Clinical Trial Update: Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assessing rivaroxaban absorption in patients with cervical spinal cord injury has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury
• Thromboembolism

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Swiss Paraplegic Research, Nottwil | Conditions: Spinal Cord Injuries, Thromboembolism | Phase 4 | Status: WITHDRAWN